OPENING SESSION

Co-Chairs: Nick Drager, TBVI (Switzerland) | Mark Feinberg, IAVI (USA) | David Lewinsohn, Working Group on New TB Vaccines (USA)

Welcome Remarks
Global Forum Co-Chairs: Nick Drager, TBVI; Mark Feinberg, IAVI; David Lewinsohn, WGNV
Stop TB Partnership: Lucica Ditiu (Switzerland)

Keynote Address
Honorable Dr. Harsh Vardhan, Union Minister of Health and Family Welfare, Science and Technology and Earth Sciences, Government of India; Chairman, Stop TB Partnership Board (India)

Keynote Presentation
Helen Rees Wits RHI, Wits University (South Africa)

Opening Remarks
Emilio A. Emini, Bill & Melinda Gates Foundation (USA)
Emily Erbelding, NIAID Division of Microbiology and Infectious Diseases (USA)
Michael Makanga, European & Developing Countries Clinical Trials Partnership (Netherlands)

SCIENTIFIC SESSION: NOVEL INSIGHTS AND APPROACHES TO TB VACCINE R&D

Part I: Granulomas: Novel insights into an ancient structure
Visualizing immunosuppressive microenvironments in *Mycobacterium tuberculosis* granulomas
Michael Gerner, University of Washington, Department of Immunology (USA)
Insights into features of bacterial control from single cell profiling of TB granulomas
Hannah Priyadarshini Gideon, University of Pittsburgh School of Medicine (USA)

Part 2: Novel Insights into protective immunity
Vaccination – intended and non-intended consequences
Andrea M. Cooper, University of Leicester (UK)
Dissecting antibody functions in tuberculosis
Lenette Lu, Division of Infectious Diseases and Geographic Medicine, UT Southwestern Medical Center (USA)

Part 3: Novel vaccine delivery platform
mRNA vaccines against tuberculosis
Mustafa Diken, BioNTech (Germany)

SPECIAL SESSION: ACCELERATING TB VACCINE RESEARCH AND DEVELOPMENT: LAUNCH OF A GLOBAL ROADMAP

Co-Chairs: Mark Hatherill, South African Tuberculosis Vaccine Initiative (South Africa) | Matteo Zignol, Global TB Programme, World Health Organisation (Switzerland)

The TB vaccine roadmap: actions and enabling considerations
Frank Cobelens, Amsterdam Institute for Global Health and Development (AIGHD) (Netherlands)

Opportunities for TB vaccine R&D
Willem Hanekom, Africa Health Research Institute (AHRI) (South Africa)

A community perspective on the TB vaccine R&D roadmap
Blessina Kumar, Global Coalition of TB Activists (India)

Panel discussion featuring
• Videlis Nduba, Kenya Medical Research Institute (KEMRI) (Kenya)
• Ann Ginsberg, Bill & Melinda Gates Foundation (USA)
**SCIENTIFIC SESSION: CLINICAL DEVELOPMENT OF NEW TB VACCINES**

**9:00 – 10:30**

**Format:** Co-Chairs: Ann Ginsberg, Bill & Melinda Gates Foundation (USA) | Monde Muyoyeta, Centre for Infectious Disease Research in Zambia (Zambia)

**Advancing TB vaccine candidates in the clinic**
Ann Ginsberg, Bill & Melinda Gates Foundation (USA)

**Update on development activities for M72/AS01e**
Alexander Schmidt, Bill & Melinda Gates Medical Research Institute (USA)

**The DAR-901 prevention of infection trial**
C. Fordham von Reyn, Dartmouth Geisel School of Medicine (USA)

**MTBVAC, an attenuated TB vaccine: looking towards the efficacy trial**
Ingrid Murillo Jelsbak, Biofabri, Zendal Group (Spain)

**The tuberculosis vaccine H56:IC31**
Álvaro Borges, Center for Vaccine Research, Statens Serum Institut (Denmark)

**A brief update on the VPM1002 vaccine candidate**
Sajjad Desai, Serum Institute of India Pvt Ltd. (India)

**From TB to COVID and back again: public involvement as an essential science**
Anastasia Koch and Cheleka Ann-Marie Mpande, Ehlwoza (South Africa)

**10:30 – 10:45**

**BREAK**

**10:45 – 11:45**

**PANEL DISCUSSION: POLICY AND ACCESS ISSUES FOR TB VACCINES**

Co-Chairs: Alejandro Cravioto, Facultad de Medicina, Universidad Nacional Autónoma de México (Mexico) | Shelly Malhotra, IAVI (USA)

**Opening Remarks**
Stéphanie Seydoux, French Ambassador for Global Health, French Republic

**Panel Discussion**
- Gagandeep Kang, Christian Medical College (India)
- Luciana Leite, Instituto Butantan (Brazil)
- Evaline Kibuchi, Stop TB Partnership Kenya (Kenya)
- Muhwa Jeremiah Chakaya, London School of Hygiene and Tropical Medicine; Respiratory Society of Kenya (Kenya)
- Deepali Patel, Gavi, the Vaccine Alliance (Switzerland)
- Cherise Scott, UNITAID (Switzerland)

**11:45 – 12:00**

**BREAK**

**12:00 – 13:00**

**SPONSORED SESSION: IMPACT OF TB PREVENTIVE TREATMENT (TPT) AS STANDARD OF CARE ON TB VACCINE DEVELOPMENT**

Interactive roundtable discussion featuring:
- Ghiorghis (George) Belai, FHI Clinical (Kenya)
- Falgueree K. Parekh, EpiPointe (USA)
- Jon (Ben) Woods, Physician, Pediatric Infectious Disease (USA)
- Carole D. Mitnick, Department of Global Health & Social Medicine, Harvard Medical School (USA)

*This session is sponsored and organized by FHI Clinical.*
12:00 – 13:30  WORKSHOP: ADVOCACY FOR RESEARCHERS

What is advocacy and why is it important for researchers to advocate?
- Uvi Naidoo, Pediatrician (South Africa)
- David Lewinsohn, Working Group on New TB Vaccines; Oregon Health & Science University (USA)
- Nandita Venkatesan (India)

Advocating to governments for policies and funding
- Evaline Kibuchi, Global TB Caucus Africa Region; Stop TB Partnership Kenya (Kenya)
- Augstin Martin, DSW (Germany/EU)

Advocating to communities and civil society to increase knowledge and interest
- Anastasia Koch, Eh!woza (South Africa)
- Rosa Herrera, Global TB CAB; TB Proof (Mexico)

How to communicate scientific findings for advocacy
- Cheleka Mpande, Eh!Woza; South African Tuberculosis Vaccine Initiative (South Africa)
- Laia Ruiz Mingote (Spain)

Tools for advocacy
- Rabita Aziz, Infectious Diseases Society of America (USA)
- Rhea Lobo, Bolo Didi (Denmark)

This workshop is organized by the Stop TB Partnership Working Group on New TB Vaccines Advocacy Subgroup.

Thursday 22 April 2021

9:00 – 10:30  SCIENTIFIC SESSION: BCG, 100 YEARS LATER

Co-Chairs: Camille Locht, Inserm; Center for Infection and Immunity of Lille, Institut Pasteur de Lille (France) | Puck Teetje Pelzer, KNCV Tuberculosis Foundation (Netherlands)

BCG: What have we learnt in 100 years?
- Helen McShane, The Jenner Institute, University of Oxford (UK)

Trained immunity as a mechanism behind the wider applicability of BCG
- Simone A. Joosten, Department of Infectious Diseases, Leiden University Medical Center (Netherlands)

BCG clinical trials for COVID-19 and other respiratory infections
- Nigel Curtis, The University of Melbourne; Murdoch Children's Research Institute (Australia)

BCG revaccination: trial endpoints and potential policy impact
- Gavin Chuchyard, Aurum Institute (South Africa)

Potential effect of disruptions to BCG vaccination on global paediatric tuberculosis mortality
- Richard G. White, Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine (UK)

10:30 – 10:45  BREAK

10:45 – 11:45  PANEL DISCUSSION: LEVERAGING COVID-19 TO ADVANCE TO VACCINE R&D

Co-Chairs: Gerald Voss, TBVI (Belgium) | Julio Croda, Oswaldo Cruz Foundation; School of Medicine, Federal University of Mato Grosso do Sul (Brazil)

Panel Discussion
- Valerie Oriol Mathieu, Janssen Infectious Diseases and Vaccines (Netherlands)
- Nicole Lurie, Coalition for Epidemic Preparedness Innovations (UK)
- Jim Kublin, HVTN; Fred Hutchinson Cancer Research Center (USA)
- Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory (South Africa)
- Gordon Dougan, Wellcome Sanger Institute (UK)
- Hassan Mahomed, Stellenbosch University (South Africa)

11:45 – 12:00  BREAK

12:00 – 13:00  PANEL DISCUSSION: CLOSING THE FINANCING GAP FOR TB VACCINE R&D

Co-Chairs: Glaudina Loots, Department of Science and Technology (South Africa) | Mike Frick, Treatment Action Group (USA)

Panel Discussion
- Shiva Dustdar, European Investment Bank (Luxembourg)
• Manjula Singh, Indian Council on Medical Research (India)
• Lucica Ditiu, Stop TB Partnership (Switzerland)
• Nicolas Menzies, Harvard T.H. Chan School of Public Health (USA)
• Hon. Dr. Sibongiseni Dhlomo, National Assembly in Parliament; National TB Caucus (South Africa)

13:00 – 13:30 CLOSING SESSION

Co-Chairs: Nick Drager, TBVI (Switzerland) | Mark Feinberg, IAVI (USA) | David Lewinsohn, Working Group on New TB Vaccines (USA)

Closing Remarks
Eric Goosby, UCSF Gladstone Center for AIDS Research; UN Secretary-General’s Special Envoy on Tuberculosis, (USA)

Closing Address
Soumya Swaminathan, World Health Organization (Switzerland)

Remarks from 6th Global Forum Host Country
Mr. Olivier Véran, Minister for Solidarity and Health, French Republic